Format

Send to

Choose Destination
Expert Opin Ther Targets. 2014 Sep;18(9):999-1009. doi: 10.1517/14728222.2014.938050. Epub 2014 Aug 1.

cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?

Author information

1
Dublin City University, National Institute for Cellular Biotechnology , Dublin 9 , Ireland +00353 1 7007497 ; +00353 1 7005484 ; Norma.ODonovan@dcu.ie.

Abstract

INTRODUCTION:

The identification and validation of a targeted therapy for triple-negative breast cancer (TNBC) is currently one of the most urgent needs in breast cancer therapeutics. The cMET oncogene encodes a membrane-bound tyrosine kinase implicated in the formation and/or progression of several cancer types, including TNBC. Currently, inhibitors targeting cMET are undergoing clinical trials for a variety of cancers, including TNBC. These include anti-cMET and anti-hepatocyte growth factor (HGF) monoclonal antibodies and tyrosine kinase inhibitors.

AREAS COVERED:

This article reviews the structure and mode of action of cMET, the role of cMET in cancer formation/development, with particular emphasis on its role in basal/TNBC and its potential as a therapeutic target for this subtype of breast cancer.

EXPERT OPINION:

Due to cancer heterogeneity, it is unlikely that all TNBC patients will be responsive to anti-cMET drugs. Therefore, if cMET is to be used as a target for treatment, it will be important to identify predictive biomarkers to select, upfront, those patients likely to benefit. Potential predictive biomarkers for anti-cMET treatments in basal/TNBC include cMET, phospho-cMET, downstream signaling proteins or HGF. These putative predictive biomarkers should be evaluated in a large panel of basal/TNBC cell lines before incorporation into clinical trials involving anti-cMET drugs.

KEYWORDS:

basal; breast cancer; cMET; targeted therapy; triple-negative

PMID:
25084805
DOI:
10.1517/14728222.2014.938050
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center